These results led to the hypothesis that IL-23 signaling is not essential for NASH pathogenesis in preclinical models and that blocking this pathway may not be a successful therapeutic strategy to slow the disease progression in NASH patients [13]. Here, IL23A is linked to metabolic dysfunction-associated steatohepatitis.